The panel, What It Takes To Build A Successful, Regional BioInnovation Hub (sponsored by Independence Blue Cross) focuses on Philadelphia — one of many cities seeking to support the continued growth of cell and gene therapy and connected health industries.
Here's a preview of some of the panel discussions at INVEST Precision Medicine, including diagnostics, investment trends, and building a bioinnovation hub.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
What needs to happen to facilitate data sharing, ensure access to genome sequencing and promising personalized therapies?
The Federal Trade Commission and its U.K. counterpart concluded that Roche would not likely have an incentive to delay or discontinue development of Spark's hemophilia A gene therapy. Roche markets a monoclonal antibody for the same disease.
Nine senators sent a letter to FTC Chairman Joseph Simons urging greater scrutiny over like the one between BMS and Celgene, expressing concern over antitrust issues, innovation and drug pricing.
The payer unveiled Embarc Benefit Protection, which it said would enable plans to pay a monthly, per-member fee to enroll, while patients would not have to pay anything out of pocket.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
While well-developed in cancers, precision medicine's readiness for prime time beyond oncology varies markedly from disease to disease. But reimbursement remains a significant hurdle.
In a fireside chat at the recently concluded Veeva Summit in Philadelphia, Jeff Marrazzo said payment over time is important for gene therapies, but the pace of policy making by government is too slow.
A company's journey from launch to acquisition is rarely a straight path. It involves overcoming many challenges and obstacles, especially for a pioneering gene therapy company. In this special report, Spark Therapeutics' journey offers some interesting insights into the evolution of a life science business and how it finds an exit.
The biotech company said the deal would allow it to strengthen its ophthalmology pipeline. It follows last week's acquisition of Spark Therapeutics by Roche for $4.8 billion.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Shares of Philadelphia-based Spark were up more than 120 percent in premarket trading on the Nasdaq following the news.
Hospitals - especially in Europe - anticipate growing interest from international patients. But a wave of industry consolidation is debatable.
The company expects reimbursement decisions by national-level authorities in 2019 and 2020. The UK's NICE recommended Cancer Drugs Fund coverage for another high-priced Novartis therapy, the CAR-T Kymriah, earlier this month.
With a positive CHMP decision, the European Commission is expected to rule in two months, but equity research analysts foresee significant headwinds for the gene therapy.
Spark Therapeutics claimed a number of firsts on Tuesday, with the historic approval of its one-time gene therapy, Luxturna, for the treatment of adults and children with an inherited retinal disease.